---
schema_version: "secwatch.filing_event.v1"
accession: "0001390478-24-000022"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:50:59.106530+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SELLAS Q3 net loss narrows to $7.1M; Phase 3 AML interim analysis on track for Q4 2024

## Summary
- Q3 net loss $7.1M ($0.10/sh) vs $9.3M ($0.33/sh) in Q3 2023; cash $21M.
- Phase 3 REGAL (GPS) in AML: interim analysis of 60 events on track for Q4 2024.
- FDA granted Rare Pediatric Disease Designation (RPDD) to GPS for pediatric AML.
- SLS009 Phase 2a data in r/r AML to be presented at ASH Dec 8; 31% overall response.
- R&D expenses $4.4M (-24% YoY); G&A expenses $3.0M (-14% YoY).

## SEC filing metadata
- accession: 0001390478-24-000022
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000139047824000022/0001390478-24-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000139047824000022/sls-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001390478-24-000022
- JSON: https://secwatch.observer/filing/0001390478-24-000022.json
- Plain text: https://secwatch.observer/filing/0001390478-24-000022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.